Lacidipine: Effects on vascular pressor responses throughout the dosage interval in normotensive subjects

British Journal of Clinical Pharmacology

Volumn 46, Issue 2, 1998, Pages 127-132

  Ueda, Shinichiro ^a   Donnelly, Richard ^a   Panfilov, Vsevolod ^a   Morris, Andrew D ^a   Elliott, Henry L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Duration of action; Lacidipine; Vascular responsiveness; Vasoconstrictor agonists

Indexed keywords

ANGIOTENSIN; CALCIUM ANTAGONIST; LACIDIPINE; NORADRENALIN; PLACEBO;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

ADULT; ANGIOTENSIN II; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; EXANTHEMA; HUMANS; MALE; NOREPINEPHRINE; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0031830506     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00760.x     Document Type: Article

References (16)

1. Gaviraghi G. Lacidipine, a new 1,4-dihydropyridine calcium channel antagonist possessing a potent and long-lasting antihypertensive activity. In Trends in medicinal chemistry 1988, ed Van der Groot N, Domany G, Pallas L, Timmerman H. Amsterdam: Elsevier. 1989: 675-690.
2. Herbette LG, Gaviraghi G, Tulenko T, et al. Molecular interaction between lacidipine and biological membranes. J Hypertens 1993; 11 (Suppl 1): S13-S19.
3. Elliott HL, Pasanisi F, Sumner DJ, Reid JL. The effect of calcium channel blockers on alpha1- and alpha2-adrenoreceptor-mediated vascular responsiveness in man. J Hypertens 1985; 3 (Suppl 3): S235-S237.
4. Pasanisi F, Elliott HL, Meredith PA, Sumner DJ, Reid JL. Effect of calcium channel blockers on adrenergic and nonadrenergic vascular responses in man. J Cardiovasc Pharmacol 1985; 7: 1166-1170.
5. Murphy MB, Brown MJ, Scriven AJI, Heavey DJ, Dollery CT. Nifedipine and alpha adrenoreceptor antagonism, Clin Pharmacol Ther 1984; 36: 745-749.
6. Ueda S, Meredith PA, Howie CA, Elliott HL. A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects. Br J Clin Pharmacol 1993; 36: 561-566.
7. Sumner DJ, Elliott HL. The pressor dose-response in clinical cardiovascular pharmacology. Br J Clin Pharmacol 1987; 23: 499-503.
8. da Prada M, Zurcher G. Simultaneous determination of plasma adrenaline, noradrenaline and dopamine in the femtomole range. Life Sci 1976; 19: 1161.
9. Derkx FHM, Boomsma F, Tan-Tjiong HL, Schalekamp MADH. Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system. Clin Exp Hypertens 1972; 2: 575-592.
10. McKenzie JK, Clements JA. Simplified radioimmunoassay for serum aldosterone ultilising increased antibody specificity. J Clin Endocrinol Metab 1974; 38: 622-627.
11. Hall ST, Harding SM, Evans GL, Pellegatti M, Rizzini P. Clinical pharmacology of lacidipine. J Cardiovasc Pharmacol 1991; 17 (Suppl 4): S9-S13.
12. Lyons D, Fowler G, Webster J, Hall ST, Petrie JC. An assessment of lacidipine and atenolol in mild to moderate hypertension. Br J Clin Pharmacol 1994; 37: 45-51.
13. Perelman M. Selection of initial and maintenance dosages for lacidipine, a new once-daily calcium antagonist for the treatment of hypertension. J Cardiovasc Pharmacol 1991; 17 (Suppl 4): S14-S19.
14. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In Hypertension: Pathophysiology, Diagnosis and Management, Second Edition, eds Laragh JH, Brenner BM, Raven Press Ltd, New York 1995, pp. 2815-2825.
15. Bainbridge AD, Herlihy O, Meredith PA, Elliott HL. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices, Eur J Clin Pharmacol 1993; 45: 425-430.
16. Palatine M. Ambulatory blood pressure monitoring in the assessment of antihypertensive treatment; 24 hour blood pressure control with lacidipine once a day. J Hypertens 1991; 9 (Suppl 3): S61-S66.